Clinical Development Outsourcing Models (2nd edition)

Report Overview

Most pharma companies no longer outsource simply because they have to.  Most now recognize value in the use of contract organizations. But while the evolution of pharma’s outsourcing philosophy has been fairly uniform across companies, the application of outsourcing strategy remains highly diverse. The real trick for a head of R&D is identifying which model is best given the particular pharma company’s culture, infrastructure for clinical trial management, infrastructure for CRO management, depth of pipeline, and a host of other factors.

How you can use this report:

For Study Sponsors: Pharma buyers of this report are encouraged to use its content to navigate the benefits and drawbacks of available outsourcing models by examining what’s working and not working for other companies and why.

For Service Providers: Service providers are encouraged to use the report’s content to plan for the rise of some models, the decline of others, identify the drivers of success for these models, and anticipate customers’ need accordingly

Report Contents:

Executive Summary

Clinical Development Outsourcing Dynamics

• Outsourcing Cost Breakdown by Function
• Outsourcing Difficulties
• In-House and Outsourcing Model Allocation
• Preferred Service Provider Type by Phase
• Roles and Responsibilities that Influence Service Provider Selection

Outsourcing Models: Performance, Selection, and Use

• Analysis of each outsourcing model evaluated including model performance and reasons for use

Future Trends

• Likelihood to Deviate from Current Model
• Likelihood to Change Service Providers Based on Trends

Study Data